Sabah Oney

Sabah Oney, Ph.D., joined ARCH as a Venture Partner in 2021.
In this capacity, Dr. Oney is focused on the creation and development of new biotechnology companies.
Prior to joining ARCH, Dr. Oney was the Chief Business Officer of Alector, a biotech company working on leveraging the immune system to discover cures for neurodegenerative diseases.
At Alector, he served as a member of the Executive Committee and played a significant role in company’s growth and guided the company through several milestones including its IPO and several major partnerships.
Prior to Alector, Dr. Oney was at Ariosa Diagnostics, a biotechnology company focusing on cell-free DNA based non-invasive genetic testing where he played a pivotal role overseeing the global expansion of company’s products.
Ariosa was acquired by Roche in 2015.
Prior to that, Dr. Oney was a senior scientist at a biotechnology startup focused on a systemic siRNA-delivery platform technology.
Dr. Oney holds a B.S.
degree in Genetics from The University of Kansas where he was a Fulbright Scholar, a Ph.D.
in Genetics and Genomics from Duke University, and an M.B.A.
from The Stanford University Graduate School of Business.